Amgen, headquartered in Thousand Oaks, California, is a global biopharmaceutical company specializing in the development, manufacturing, and commercialization of innovative medicines. Founded in 1980 by William K. Bowes Jr., George B.

Rathmann, Joseph Rubinfeld, and venture capitalist Dennis W. J. Slamon, Amgen quickly emerged as a pioneer in biotechnology.

Amgen's headquarters encompasses an impressive 75-acre campus that includes state-of-the-art research and development facilities. This facility serves as the hub for the company's global operations, which extend to more than 100 countries. Additionally, Amgen operates various manufacturing facilities across the United States, Europe, and Asia.

The company's product portfolio is focused on a wide range of therapeutic areas, with particular expertise in immunology, oncology, nephrology, and cardiology. Some of Amgen's flagship products include Enbrel (for rheumatoid arthritis and psoriasis), Neulasta and Neupogen (for chemotherapy-induced neutropenia), Prolia and Xgeva (for bone health), and Repatha (for cholesterol management). Amgen has established several noteworthy partnerships and subsidiaries to expand its global reach and enhance its product offerings.

In 2013, they entered into a collaboration agreement with AstraZeneca to jointly develop and commercialize clinical-stage inflammation medicines. Amgen has also acquired companies like deCODE Genetics and Onyx Pharmaceuticals to strengthen its research capabilities and diversify its product pipeline. In terms of market position, Amgen consistently ranks among the world's leading biotechnology companies.

With global sales of approximately $25 billion in 2020, it competes with industry giants like Roche, Novartis, and Pfizer. Amgen's ability to develop breakthrough therapies and leverage its strong commercial reach contributes to its competitive advantage. A significant event in Amgen's history was the approval and launch of their groundbreaking drug, Repatha, in 2015.

This innovative cholesterol-lowering therapy represents a major milestone in Amgen's commitment to improving patient outcomes and revolutionizing healthcare. As of the latest updates, Amgen continues to invest heavily in research and development to expand its product pipeline and advance scientific innovation. The company remains at the forefront of biotechnology, striving to develop transformative therapies to address significant unmet medical needs worldwide